MPM Capital and Qiming Venture Partners USA have co-led a series A round for Umoja Biopharma, based on research at Purdue University and Seattle Children’s Research Institute.

Umoja Biopharma, a US-based in-vivo immunotherapy platform developer exploiting research from Purdue University and Seattle Children’s Research Institute, launched with a $53m series A round on Wednesday co-led by MPM Capital and Qiming Venture Partners USA. Founded in early 2019, Umoja is working on an integrated in-vivo immunotherapy platform targeting blood cancers and solid tumours,…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.